(+)-VINCRISTINE
Recurrent Adult Brain Tumor
NaviFUS CorporationSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Recurrent Adult Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 2 | BBB |
Temsirolimus M.D. Anderson Cancer Center | Phase 2 | BBB |
FLUDEOXYGLUCOSE Algemeen Ziekenhuis Maria Middelares | Phase 2 | BB |
Sorafenib National Cancer Institute (NCI) | Phase 2 | BB |
Vorinostat H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | BB |
View all 38 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →